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Abstract
Placebo treatments can be used to elicit many different physiological responses;
however, the underlying mechanisms responsible remain unclear. Recent research has
shown the possibility of a genetic influence on the placebo response in patients with
mood disorders. In this study, we attempted to establish a similar relationship in healthy
college-aged students. Force production was measured by isometric knee extension of
the quadriceps muscles using maximum voluntary contractions (MVC). Subjects were
given placebo treatments disguised as an undisclosed sports supplement with the
information that the supplement was previously shown to provide immediate strength
improvements following ingestion. Subject DNA was genotyped for two genetic
polymorphisms, tryptophan hydroxylase-2 (TPH2) and monoamine oxidase A (MAO-A).
These particular polymorphisms were chosen for study based on previous research and
their possible relationships to athletic performance. Results showed a 4.4% improvement
in peak force with the ingestion of the placebo for both men and women (p < 0.05). We
also found that the average placebo effect was similar for both genders (3.37%
improvement in males, 7.47% in females). Neither polymorphism displayed a significant
effect on the presence of the placebo response. We concluded that while a placebo
response was evident with MVC isometric force production, TPH2 and MAO-A were not
likely to be responsible for the effect.
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Chapter I: Introduction
The most common protocol for proving the efficacy of a new drug or supplement
is to design a randomized, double-blind study that allows the effects of the drug or
supplement to be compared to those of a placebo. If the drug or supplement provides
more positive or beneficial results than the placebo, the drug or supplement is said to be
effective. Until recently, placebo effects have always been attributed to biological or
psychological factors yet to be fully identified (24).

However, recent research has

evaluated specific genetic polymorphisms predisposing responders to placebo treatments.
Furmark et al. monitored amygdala response in participants with social anxiety disorder
(SAD) (6).

The amygdala is the portion of the brain that monitors and processes

emotions. Decreased activity in the amygdala is associated with low amounts of stress;
SAD patients strive to achieve this through medications and therapy. Furmark et al.
observed the greatest placebo response with subjects who carried the G allele in the
tryptophan hydroxylase-2 (TPH2) gene (6). These same subjects experience a naturally
lower amount of amygdala activity in the brain as a result of their genotype. Similarly,
Leuchter et al. studied patients diagnosed with major depressive disorder (MDD) and
found that subjects with a moderate or intermediate rate of monoamine oxidase A (MAOA) enzymatic activity experienced the greatest degree of placebo response (11). MAO-A
is an enzyme that facilitates the catabolism of norepinephrine, a process that can lead to
symptom relief for MDD patients. The intermediate rate of enyzme activity was found in
females with the heterozygous G/T expression of the gene. Because of the sex-linked
nature of this polymorphism, males can only code for the high-rate expression (G allele)
or low-rate activity (T allele).
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Research has shown that placebos are capable of producing similar or greater
effects than many sports supplements. Beedie et al. demonstrated that athletes given a
hypothetical ergogenic aid coupled with positive information regarding the substance
maintained sprint times in a repeat-sprint trial of 30 meters, whereas negative information
led to trial times 2% slower than baseline values (1). Clark et al. evaluated differences in
power output during 40-km cycling time trials when subjects were given a placebo versus
a carbohydrate supplement dissolved into a drink (4). Subjects in each supplement group
were further divided into three subgroups based on what each subgroup was instructed
about their particular drink contents: told carbohydrate, told placebo, and not told.
Subjects who were given the placebo but were told they received the carbohydrate
beverage experienced an average of 7% improvement in power, the greatest change out
of any subgroup. Pollo et al. showed that the perception of taking an ergogenic aid could
increase quadriceps muscle performance and decrease muscle fatigue (17). Two groups
were used: a supplement group and a control group. Subjects were not blinded to which
group they were assigned to; however, neither group actually received any form of an
ergogenic aid. Muscle performance was assessed over the course of four trials as the
number of repetitions generated by the quadriceps at 60% of 1RM and the total work
performed in each session. Without informing the subjects, trials 2 and 3 were actually
performed at 45% of 1RM to further the deception of the efficacy of the ergogenic agent.
Compared with baseline data, the supplement group showed an improvement of 22%.
Countless other studies have shown significant placebo responses to ergogenic aids;
however, the potential genetic effect on the placebo response to an ergogenic aid has not
been evaluated (1, 2, 4, 5, 8, 12, 14, 17). The primary objective of this study, therefore, is
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to determine if a genetic link exists between a specific genetic polymorphism and the
ergogenic response to a placebo.
More specifically, we seek to determine if a genetic link exists between a person’s
susceptibility to a placebo purported to be an ergogenic aid and either the monoamine
oxidase A or the tryptophan hydroxylase-2 gene polymorphisms. These polymorphisms
have been chosen because of the promising data shown previously (6, 11). Furthermore,
because of their relations to emotional processing and pain relief, both polymorphisms
may play a role in athletic performance.

The implications of establishing such a

connection are considerable. Particularly, if certain people are genetically inclined to
react to a placebo, the “gold standard” of drug testing with comparison to a placebo may
no longer apply without prior genotype screening of participants.

Also, if medical

conditions can be treated and alleviated with a placebo, a moral issue arises of whether or
not to lie to a patient about a treatment. The two major studies focusing on genetics and
the placebo response that were previously mentioned focused on patients with mood
disorders. To date, no study has yet examined the placebo effect in healthy subjects or in
conditions where the placebo is supposed to elicit improvements in physical performance.
Therefore, this study will compare the maximum voluntary contractions (MVC) of the
quadriceps muscles in physically active subjects on two separate occasions – with and
without ingestion of a supposed performance-enhancing supplement. Results will then be
characterized by the genotypes of the subjects to determine if there is a genetic link.

Chapter II: Background
I. Eliciting placebo response through deception in athletic performance
Author/Year Sample Training
Intervention
Size
Status
Informed
Received
Maganaris et
11
Elite
Trial 1 – both
Placebo for all
al. 2000
weightlifters groups given groups and trials
(12)
anabolic
steroid;
Trial 2 –
Group 1:
anabolic
steroid,
Group 2 placebo
Clark et al.
43
Sub-elite
Group 1 –
Each group
2000
endurance
carbohydrate randomized – half
(4)
cyclists
beverage;
received
Group 2 –
carbohydrate, half
non-caloric
received placebo
sweetener
beverage;
Group 3 –
50:50 chance
of receiving
carbohydrate
beverage
Beedie et al.
7
Competitive
0 mg/kg,
Placebo
2006
cyclists
4.5 mg/kg or
(2)
9.0 mg/kg of
caffeine
Beedie et al.
2007
(1)

42

team-sport
athletes

Group 1 –
repeat-sprint
and endurance
performance
enhancer
Group 2 –
endurance
performance
enhancer,
negative
impact on
repeat-sprint
performance

200mg of
cornstarch

McClung and
Collins 2007

17

Sub-elite
endurance

Treatment 1 –
sodium

Treatment 1 –
sodium

Findings
3.8% improvement
in strength
performance when
subjects believed
they were given
steroids

4.3% increased
mean power when
subjects believed
they were ingesting
carbohydrate and
were given placebo

2.2% increased
power output when
subjects believed
they had ingested
caffeine
Group 1(with
positive
information
regarding
treatment) – no
difference in times
between baseline
and experimental
data; Group 2 (with
negative
information
regarding
treatment) – ran
1.7% slower than
baseline data
1.5% improvement
in 5,000m time

5
(14)

athletes

Kalasountas
et al. 2007
(8)

42

Untrained
students

Pollo et al.
2008
(17)

44

Sub-elite
athletes

Foad et al.
2008
(5)

14

Sub-elite
cyclists

bicarbonate;
Treatment 2 –
sodium
bicarbonate;
Treatment 3 –
no treatment;
Treatment 4 –
no treatment
Trial 1 –
amino acids;
Trial 2 –
Group 1:
amino acids,
Group 2: no
treatment
(negative
information
regarding
supplement)
Caffeine

Treatment 1 –
caffeine;
Treatment 2 –
caffeine;
Treatment 3 –
no treatment;
Treatment 4 –
no treatment

bicarbonate;
Treatment 2 –
placebo;
Treatment 3 –
sodium
bicarbonate;
Treatment 4 – no
treatment
Placebo for all
groups and trials

Placebo

Treatment 1 –
caffeine;
Treatment 2 –
placebo;
Treatment 3 –
caffeine;
Treatment 4 – no
treatment

trials with placebo

19.6%
improvement in
strength
performance with
positive
information
regarding
supplement

Two experiments:
Leg extension
strength increased
by 11.8% without
conditioning,
22.1% with
conditioning
0.7% improvement
in mean power with
placebo

Placebos have been shown to enhance performance for a variety of athletic
performances. Placebo treatments can improve endurance performance time trials with
both running and cycling (1, 14). Strength performance can also improve when subjects
believe that a supplement will benefit their power output (2, 4, 5, 8, 12, 17). Maganaris et
al. found that giving placebo steroid treatments to elite weightlifters collectively
improved 1RM of bench press, dead lift, and squat by 3.8% (12). Beedie et al. found that
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mean power in a 10km cycling time trial increased 1.3% when subjects believed they had
ingested 4.5 mg/kg of caffeine and 3.1% when subjects believed they had ingested 9.0
mg/kg of caffeine (2). Clark et al. found an improvement of 4.3% in mean cycling power
during a 40km time trial in response to a placebo carbohydrate beverage (4).
Interventions in these studies usually inform the subjects that one of several
widely accepted ergogenic aids – such as steroids, caffeine, sodium bicarbonate,
carbohydrate, etc. – will be given to improve athletic performance. It seems that the
greatest effects are also seen when subjects receive positive information or reinforcement
regarding the supplement (1, 8). Conversely, negative information can lead to a negative
impact on performance (1). Very little data has been seen on the ability to elicit a
placebo effect using a supplement that is unfamiliar to subjects. Using aids that are
familiar to subjects may allow for preconceived notions regarding such supplements to
dominate the subjects’ response to the placebo treatment and thus contribute to the high
degree of variability seen in placebo studies. By using an unknown sport supplement,
every subject will begin at baseline knowledge and will hopefully negate the effects of
prior beliefs.
Several other contributors may influence the magnitude of placebo response,
including sample size, subject training status, and method of performance testing. In
most cases, a larger sample size seems to relatively magnify the percent of change for
placebo treatments (4, 8, 17). Perhaps a larger sample size is needed to clearly identify if
a placebo response exists. Also, the differences in training status may greatly affect the
outcome of each study. In several studies, sub-elite athletes were used. When compared
to elite and competitive athletes, these subjects have a greater room for improvement,
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allowing for a greater chance of variability and change in performance measures.
Finally, the procedures utilized in these studies are not standardized. It is very difficult to
compare performance measures for strength improvements in 1RM to 40km cycling time
trials. Furthermore, our protocol will utilize untrained, recreationally active students and
will use force production strength measures to quantify the degree of placebo response.
By doing so, it will be much easier to compare any performance improvements seen to
existing data and will help with interpreting the results of testing.

II. Genetic determinants of placebo response
Author/Year

Disorder

Treatment

Effect of Treatment

Furmark et al.
2008
(6)

Genetic Polymorphism
Identified
TPH2 gene promoter:
homozygous GG - greatest
response

Social
study drug
reduced anxiety
Anxiety
provided by
associated with
Disorder GlaxoSmithKlin
public speaking
(SAD)
e or placebo
Leuchter et al.
Major
placebo, or 1 of alleviated symptoms
monoamine oxidase A
2009
Depressive
3 commonly
of depression
(MAO-A): GG or G (11)
Disorder
prescribed
lowest response, GT –
(MDD)
antidepressants
greatest response; Val-Met
(fluoxetine,
catechol-Ovenlafaxine, or
methyltransferase
sertraline)
(COMT): Met-Met lowest response, Val-Met
or Val-Val – higher
response

A genetic polymorphism exists when a particular gene can be clearly expressed
by two or more phenotypes or morphological traits.

Each polymorphism can be

identified according to the coding sequence found on DNA in the region specific to each
particular gene. In two separate studies, patients with mood disorders that possessed
specific alleles in two known genetic polymorphisms experienced a greater degree of
placebo response than patients who were lacking those same alleles (6, 11). The specific
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polymorphisms in question were the G-703T polymorphism of the tryptophan
hydroxylase-2 (TPH2) gene promoter in patients with social anxiety disorder and GT
polymorphism of the monoamine oxidase A (MAO-A) enzyme. Furmark et al. studied
subjects that were diagnosed with social anxiety disorder (SAD), which is characterized
by anxiety and fear from the judgment of others (6). The symptoms of SAD can be
treated with medication to alleviate anxiety by reducing stress-related activity in the
amygdala of the brain. Placebo treatments, disguised as SAD medications, have also
been shown successful in treating SAD. Patients who carry the T allele in the TPH2 gene
tend to naturally display a higher amount of amygdala activity then patients who are
homozygous for the G allele. It was observed that patients homozygous for the G allele
demonstrated the greatest response to placebo treatments with regard to SAD symptom
alleviation. Leuchter et al. evaluated subjects diagnosed with major depressive disorder
(MDD), a mood disorder characterized by chronic depression associated with symptoms
of sadness, loss, anger, or frustration (11). Monoamine oxidase A (MAO-A) is an
enzyme that facilitates the catabolism of norepinephrine. The sex-linked gene that codes
for MAO-A determines the rate of enzymatic activity: males with a single T allele or
females with T/T demonstrate the lowest-activity rate; G/T females have a moderate or
intermediate rate; G males or G/G females show the highest-activity rate. In patients
with MDD, the highest activity of MAO-A (G or G/G alleles) showed the lowest
response to placebo treatments. The intermediate rate of MAO-A activity, coded by the
G/T alleles, showed the most promising response to placebo treatments.
Current research findings cannot be generalized to a greater population because
the only research performed thus far has focused on patients with mood disorders.
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Specifically, it is unknown if genetic polymorphism can influence individuals without
mood disorders. Furthermore, it is unknown if these polymorphisms would influence the
placebo response in other situations, such as athletic performance. Thus the present study
will look at healthy subjects who are recreationally active to see if a similar genetic link
can be established for placebo effect.

III. Reliability and validity of knee extension MVC through isometric testing
Author/Year

Sample Size

Tool Utilized

Bohannon 1986
(3)
Stuberg and
Metcalf 1988
(20)
Rainoldi et al.
2001
(18)
Larsson et al.
2003
(10)
Symons et al.
2005
(21)
Kelin et al. 2008
(9)

30

Handheld dynamometer

Intersession
Correlation
0.98

14

Handheld dynamometer

0.98

9

Specially designed bed with force
transducer

0.70

20

Isokinetic dynamometer

0.93

19

Biodex

0.91

20

Handheld dynamometer

0.79

A maximum voluntary contraction (MVC) is the peak force produced by one
single contraction. Knee extension isometric MVCs have been accepted as a reliable
measure of muscular strength. Most research on the reliability of isometric MVC testing
has shown a high degree of correlation between trial sessions on different days (3, 10, 20,
21). This shows a great amount of repeatability with minimal day-to-day variability in
maximal force production.
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Many factors can contribute to variations and limit correlation. Maintaining the
same position for each test repetition is crucial. Bohannon manually braced each limb
during testing, which could contribute to intersession variance (3). Less controllable
factors such as subject moods or degree of motivation can also add day-to-day
differences (18). Kelin et al. evaluated intratester and intersession reliability by utilizing
three separate testers of varying degrees of experience in using a handheld dynamometer
(9). Both intratester and intersession results showed high correlation values and low
standard error of measurements. However, it was observed that handheld dynamometers
were likely to be contraindicated in any instance where the strength of the subject may
overpower that of the tester. For example, it was discovered during pilot testing that the
subjects’ strength in plantar flexion was greater than the testers’ ability to resist the
motion (9). This could not be remedied in any way by changing the angle at which the
test was being administered, so plantar flexion strength could not be evaluated by this
method. Therefore, the most ideal method for using these dynamometers may be to place
the subjects in a position that offers a greater mechanical advantage to the tester. Symons
et al. used a Biodex to test single-session repeatability in older men (21). The coefficient
of variation ranged from 8 to 17% for peak torque (21). The most notable aspect about
this protocol was the system developed by the tester. Every subject was given verbal
instructions regarding the testing procedure. His or her leg was then moved passively
through the range of motion. Once completed, each subject had the opportunity to
practice the test before the actual recorded test was administered. Throughout the entire
protocol, the subject was given consistent encouragement. In order to standardize this
procedure, it is important that the tester provide consistent and similar encouragement to
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every subject. Verbal feedback regarding specific force data should not be given as it
could change the subject’s motivation for the next test. The use of the Biodex also limits
the variability created by using the handheld dynamometers by facilitating reproducible
setups.

IV. Proposed mechanisms for the placebo effect
Author/Year
Voudouris et al. 1989
(22)
Voudouris et al. 1990
(23)
Montgomery and Kirsch 1996
(16)
Mayberg et al. 2002
(13)
McRae et al. 2004
(15)
Wager et al. 2007
(25)

Treatment type
Analgesic cream

Proposed mechanism
Classical conditioning

Analgesic cream

Classical conditioning

Topical anesthetic

Classical conditioning,
Expectancy theory
Expectancy theory

Antidepressant medication
Transplantation of human
embryonic dopamine neurons
in patients with advanced
Parkinson’s disease
Analgesic cream

Expectancy theory

Expectancy theory

Two main theories have been proposed to explain the psychological mechanism
for the placebo effect: classical conditioning and expectancy theory.

Classical

conditioning, as introduced by Ivan Pavlov in 1927, states that a response can be learned
when the same stimulus is applied repeatedly (19).

When the subject is properly

conditioned, a conditioned response will occur when the same stimulus is applied. The
famous example of classical conditioning, Pavlov’s dogs, demonstrated the dogs’
conditioned response (salivating) in response to the stimulus (bell) that had previously
been associated with the serving of food. Expectancy theory states that a placebo will
elicit a particular response simply because the recipient believes that it will (19). Such

12

expectations can result from advertisements, support from credible people (such as
doctors, scientists, etc.), or referrals made by trusted family or friends.
In two separate studies, Voudouris et al. placed subjects into groups to determine
which theory was responsible for the placebo effect (22, 23). In the 1989 study, two
groups of subjects were instructed that an analgesic cream would reduce skin sensitivity
and block pain (22).

Three trials were established where the pain stimulus was

incrementally increased until the subject could no longer tolerate the pain. They were
then treated with the cream and the stimulus was again applied until it was no longer
tolerable. During the second trial, the rate of increment was decreased for group I and
increased for group II without the subjects’ knowledge to simulate the conditioning
phase. Despite the expectancy that the cream would diminish the pain, group II subjects
showed a decrease in mean pain tolerance as a result of the learning that occurred in trial
2. These results were confirmed by the second study published in 1990. Using a
different methodology that both separated expectancy and conditioning and combined the
two, it was found that conditioning alone elicited a greater placebo response than
expectancy alone (23).
Mayberg et al. focused only on the expectancy theory (13). In treating clinically
depressed men, half of the men who experienced symptom remission had been given
placebos (13). No conditioning was performed on these subjects, but they were clearly
instructed on how the treatment was supposed to improve mood. Similarly, McRae et al.
found that out of the 30 subjects, the 18 that received a sham surgery versus a neuron
transplantation surgery experienced greater improvements in quality of life than the 12
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who actually received the transplant (15). Again, only the expectation that the treatment
should work was responsible for the outcome.
It seem that the literature is unclear whether one theory holds greater
responsibility than the other. Stewart-Williams and Podd suggest that perhaps both play
a key role in facilitating a placebo response (19). One can also function independently of
the other, as seen in the studies by Mayberg et al. and McRae et al. (13, 15).
Very little research has been conducted on the physiological mechanisms
surrounding the placebo response. Wager et al. has shown that despite the lack of a
pharmacological treatment in placebo pain therapy, a physiological effect can still take
place (25). Similar to the body’s response to pain medication, the expectancy of a
treatment can elicit opioid release that relieves pain. However, little is known about why
or how this occurs.

Chapter III: Methods
Subjects.
Informed consent was obtained from 54 subjects (34 male, 20 female), aged 1822. Subjects were recreationally active (minimum: 1 bout of exercise per week for 30
minutes)

college

students

from

James

Madison

University.

Upper

level

Kinesiology/Exercise Science students with prior knowledge of typical supplement
testing procedures were excluded from participation to protect the deception necessary in
this study.

Study Design.
Subjects participated in three trials on separate occasions.

The first was a

familiarization trial. Subjects were asked to perform a number of maximum voluntary
contractions (MVC) of the quadriceps muscle using a custom-built muscle function
device designed at James Madison University. The test was performed with the subject
seated upright with the self-reported dominant leg positioned at approximately 70° of
knee flexion. Each MVC was held for 3 seconds against the stationary bar, and force
production was measured from a force transducer for each contraction. A minimum of
three repetitions with a maximum of eight were used to determine maximal force output
for the trial until two numbers were generated within 20N of each other, and the results
were averaged.
The same MVC protocol was applied during the two subsequent treatment trials.
Prior to each trial, subjects ingested 50 mL of a commercial sports beverage. On one
occasion, the subjects were told that the drink contained an ergogenic aid already
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dissolved into the drink. On the other occasion (control trial), the subject was told that
the drink did not contain the ergogenic aid. Nothing was actually dissolved into the drink
on either day. MVC tests were conducted immediately following ingestion and a 5-min
warm-up (3mph on treadmill). The order of the treatment trials was randomly counterbalanced.
To prevent subjects from attempting to research the ergogenic aid thought to be
used in this study, subjects were informed that the supplement was still in its testing
phase and was not readily available on the market to consumers.

Genotyping.
Blood samples were obtained from each subject during the Familiarization Trial.
DNA was extracted from whole blood using a Qiagen kit following the manufacturer’s
protocol (Qiagen, Valencia, California). DNA samples were sent to the Center for
Genetic Medicine Research in Washington, DC for genotyping.

Specifically, the

genotyping was conducted for MAO-A and TPH-2 gene promotor. Genotyping was
blinded to subject, treatment, and treatment response.
MAOA T941G Polymorphism
To determine the presence of T- or G- allele located at mRNA position 1072 in
the coding sequence of the MAOA gene (Gene ID: 4128), a PCR product was amplified
using forward primer 5′-GAC CTT GAC TGC CAA GAT-3′ and reverse primer: 5′CTTCTTCTTCCAGAAGGCC-3′ with methods developed by Hotamisligil and
Breakefield (7). The polymerase chain reaction (PCR) was performed according to the
manufacturer’s instructions (Accuprime PCR kit, Invitrogen, US). PCR reactions (total
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volume: 20 µl) contained 50g DNA, Buffer II (40 mM Tris-HCl [pH 8.4], 100 mM KCl,
3 mM MgCl2, 400 µM dGTP, 400 µM dATP, 400 µM dTTP, 400 µM dCTP, 1U
AccuPrime Taq DNA Polymerase, thermostable AccuPrime protein, and stabilizers)
(Invitrogen), 0.1 mM/L of each primer. After the initial denaturation step at 94°C for 2
min, DNA was amplified in 35 PCR cycles (94°C for 30 sec; 60°C for 30 sec; 68°C for 1
min). Ten microliters of the PCR product was digested with 3U Fnu IV (New England
Biolabs, US), analyzed by gel electrophoresis in a 2% agarose gel containing ethidium
bromide, and visualized under UV light. When a G allele is present, digestion results in
two fragments of 65 bp whereas the absence of the Fnu IV recognition site (GCNGC)
leaves the 130-bp PCR product intact.
TPH2 (-G703T) Polymorphism
The TPH2 -G703T (rs4570625) is located in the putative transcriptional control
region of TPH2 (Gene ID: 121278). PCR was performed with the forward primer 5′TTTTATGAAAGCCATTACACAT-3′

and

the

reverse

primer

5′-

TTCCACTCTTCCAGTTATTTTA-3′ developed by Furmark et al. (6). The PCR
amplification mixture (total volume = 20 µl) contained 50g gDNA, Buffer II (40 mM
Tris-HCl [pH 8.4], 100 mM KCl, 3 mM MgCl2, 400 µM dGTP, 400 µM dATP, 400 µM
dTTP, 400 µM dCTP, 1U AccuPrime Taq DNA Polymerase, thermostable AccuPrime
protein, and stabilizers) (Invitrogen), 0.1 mM/L of each primer. Samples were amplified
using a Thermocycler (GeneAmp PCR system 2720, Applied Biosystems) for 35 cycles.
After an initial 2 min at 94°C, each subsequent cycle consisted of 30 s at 94°C, 30 s at
60°C, and 1 min at 68°C. The amplified DNA (10 µl) was digested with the 5U of the
restriction enzyme PsiI (New England Biolabs, US), which cuts at the -703T site. The
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product was electrophoresed in 2% agarose gels and stained with ethidium bromide. The
undigested PCR product carries the G variant, whereas the digested product with two
fragments of 55 and 149 bp contains the T allele. Homozygous genotypes were identified
by the presence of a single 204 bp band (G/G), or bands of 55 and 149 bp (T/T). The
heterozygous genotype had three bands: 204, 55, and 149 bp (G/T).

Statistical Analysis.
Statistical analyses were performed using the Statistical Package for the Social
Sciences version 16 (SPSS Inc, Chicago, Illinois). The placebo effect was quantified as
the percent difference between the trial in which the subject believed they were ingesting
the ergogenic aid and the control trial. Potential differences in the placebo effect were
compared across genotypes using repeated measures analysis of variance (ANOVA) with
one within-subjects effect (treatment) and two between-subjects effects (genotype and
gender).
correction.

Post-hoc differences were determined using a t-test with a Bonferroni

Chapter IV: Results
Subjects displayed a significant increase in MVC when told they were receiving a
supplement (P < 0.05) (Figure 4.1). Mean force production for the treatment without the
supplement was 487 ± 137N while the mean force production for the treatment with the
perceived supplement was 508 ± 145N.
Tables 4.1 and 4.2 summarize the percent improvement for the placebo response
for each genotype by gender. There was no main effect for gender on the placebo
response (P > 0.05). There was a 3.37% increase in force production for males and
7.47% for females with the perceived supplement. Furthermore, there was no main effect
for genotype nor a genotype x treatment interaction for either the MAO-A or TPH2
polymorphisms (P > 0.05), suggesting that neither polymorphism impacted the
magnitude of the placebo response in this sample of subjects.

Figure 4.1: Force production (* denotes significance at p < 0.05)

*

Table 4.1: Percent Improvement for the placebo for MAO-A
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Gender

Genotype

Mean

Male

G

4.6536

10.93301

8

T

2.9713

12.87901

26

Total

3.3672

12.31007

34

G

4.4591

13.07367

4

T

8.2193

10.22442

16

Total

7.4672

10.57825

20

G

4.5888

11.07650

12

T

4.9706

12.08465

42

Total

4.8857

11.76702

54

Female

Total

Std. Deviation

N

Table 4.2: Percent Improvement for the placebo for TPH2
Gender

Genotype

Mean

Male

GG

3.5772

12.84906

31

GT

1.1968

4.01843

3

Total

3.3672

12.31007

34

GG

7.3231

10.99320

17

GT

8.2839

9.75005

3

Total

7.4672

10.57825

20

GG

4.9039

12.23930

48

GT

4.9706

12.08465

6

Total

4.8857

11.76702

54

Female

Total

Std. Deviation

N

Chapter V: Discussion
The primary finding of the present study is that MVC force production was
elevated by 4.4% when subjects believed they had ingested an ergogenic aid. This
placebo effect reaffirms that supplement and drug efficacy studies should utilize doubleblind protocols. If subjects are not blinded to which intervention they are receiving, it
would be hard to prove that any given substance is more effective than not giving any
substance at all.

Also, by limiting the subjects’ prior knowledge about the sport

supplement, the tester was able to provide the same information regarding the supplement
and its supposed effects to every subject, likely increasing the impact of the placebo
response.
The increase in force production also confirms that a placebo response can be
demonstrated with maximal strength testing. The change of +4.4% in maximal force
production is consistent with both the 3.8% improvement in 1RM demonstrated by
Maganaris et al. and 4.3% increase in mean power during a 40km cycling time trial by
Clark et al. (4, 12). The study conducted by Kalasountas et al. was most similar in
subjects and methods to our study (8). Specifically, the authors also examined untrained,
recreationally active college-aged students as subjects, and performance measures were
strength measurements. Kalasountas et al. also included a treatment/no-treatment group
similar to the intervention protocol we used (8). However, our findings showed a much
smaller improvement in change in force (4.4% versus 19.6%). This could be due to the
use of 1RM bench press and leg press to evaluate strength changes in the study by
Kalsountas et al. while we looked at isometric strength of the quadriceps muscles only
(8).
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Gender did not impact the magnitude of the placebo effect; both males and
females demonstrated a similar degree of placebo response. Males experienced a 3.39%
increase while females experienced a 6.70% increase in force production. These changes
were not significantly different from one another. Therefore, future placebo studies need
not discriminate potential subjects based on gender.
Neither of the genetic polymorphisms selected for this study (TPH2 and MAO-A)
influenced the placebo response to a perceived sports supplement.

These two

polymorphisms selected were chosen based on the promising results seen in previous
studies and the possibility of their impact on athletic performance (6, 11). Furmark et al.
observed the greatest placebo response with SAD patients who carried the G allele in the
TPH2 gene (6). As a result of their genotype, these same subjects experience a naturally
lower amount of amygdala activity in the brain, which leads to lower stress levels. In the
study by Leuchter et al., MDD patients with a moderate or intermediate rate of MAO-A
enzymatic activity experienced the greatest degree of placebo response (11). This trait
was found in females with the heterozygous G/T expression of the gene. Because of the
sex-linked nature of this polymorphism, males can only code for the high-rate expression
(G allele) or low-rate activity (T allele). In this study, subjects who carried either the G
allele in the TPH2 gene or the G/T expression of the MAO-A gene or both did not
experience a significantly higher magnitude of placebo response than the subjects who
possessed other gene expressions. However, these genetic links may only be evident in
patients with mood disorders. The underlying conditions of social anxiety disorder or
major depressive disorder may have influenced the findings of the previous studies, and
the lack of such conditions in this study could account for the different results. Also,
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quantifying a psychological response to a treatment such as “alleviating anxiety” may be
more subjective than measuring force production. It is difficult to maintain consistency
in evaluation when subjects self-report the degree of their symptom resolution, and the
data results may not be comparable to the results of our study.
There were several limitations to this study that should be noted. First, the sample
size may not have been large enough to observe significant differences between genetic
groups. With genetic research, larger sample sizes are needed because the testing pool
quickly diminishes when subjects are divided into sub-groups based on their genetic
characteristics. However, there was no trend present to suggest that a larger sample size
may have led to any significant findings (MAO-A p = 0.77; TPH2 p = 0.74). The second
limitation was that the polymorphisms selected for this study might have limited the
scope of possibility. TPH2 and MAO-A have been shown to be influential in patients
with mood disorders; however, they may not exhibit the same influence in healthy
subjects. A third limitation was the use of isometric force as the measure of force
production. Isometric force does not translate to other methods of force production
because of the lack of movement through the joint’s range of motion. Also, strength tests
may not fatigue the subject enough to elicit a genetically-influenced placebo response.
Endurance training protocols that are longer in duration may allow more time for the
deception to affect the subject psychologically. Isometric testing was used in this study
because of its simplicity and low daily variability. Data on the reliability of MVC force
production on a day-to-day basis indicates a high degree of reproducibility (3, 10, 20, 21).
However, our findings strongly suggest that while a placebo response can be generated
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with such a simple protocol, there is a lack of genetic effect associated with this particular
protocol.
In summary, a placebo response can be elicited with MVC force production of the
quadriceps. This can be seen in both males and females. However, our findings suggest
that the TPH2 and MAO-A gene polymorphisms do not influence the likelihood of a
placebo response. Future studies should consider other polymorphisms that are not
influenced by the presence of mood disorders or other underlying conditions.
Furthermore, larger sample sizes and a different exercise protocol might influence future
results.
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Appendix I
Consent to Participate in Research
Identification of Investigators & Purpose of Study
You are being asked to participate in a research study conducted by Jennifer Wu from
James Madison University. The purpose of this study is to determine if genetics affect
the training response obtained by ingestion of a specific supplement.

Potential Risks & Benefits
If you choose to participate in this study, you will perform three separate trials of a
maximum voluntary contraction of the thigh muscle. The investigator perceives the
following are possible risks arising from your participation in the study: nausea,
discomfort, dizziness, and in rare occurrences, heart attack, stroke or death. However,
you were chosen for this study because of your low risk for these occurrences. In healthy
individuals, the risk of death during vigorous exercise has been estimated at 1 death per
year for every 18,000 individuals.

Potential benefits from participation in this study include:
1) Helping with research that may improve the effectiveness of supplementation by
targeting people for whom it will be most effective.
2) Knowledge of your maximal voluntary contraction
3) Knowledge of whether you are a responder to this particular supplement.
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Research Procedures
Should you decide to participate in this research study, you will be asked to sign this
consent form once all of your questions have been answered to your satisfaction. This
study consists of three separate trials of a maximum voluntary contraction of the thigh
muscle. All testing will occur in Godwin Hall, room 209, on the campus of James
Madison University. Furthermore, you will be asked to regulate your diet intake
according to specific guidelines prior to every testing session. All tests will be separated
by at least 48 hours, so that you will be tested three times over a two to three week
period, for a total of approximately three hours of testing. A blood draw will also be
taken at the first testing session for the purpose of genotyping.

Maximum voluntary contraction: These three test sessions will be performed at the same
time of day each time. You will be asked to refrain from food and beverages (except
water) for two hours prior to these tests. In addition, you will need to refrain from
consumption of caffeine-containing beverages (coffee, tea, cola drinks, cocoa) for 24
hours prior to the test. During these three test sessions, you will maximally contract your
thigh muscle against an unmoving knee extension bar. This test will be performed three
times during each session, and the average score will be calculated for each session. Ten
minutes prior to each test, you will ingest an 8 oz. portion of a popular sports beverage
either with the supplement dissolved into the beverage or without the supplement.
Between test preparation and completion of these exercise tests, each test should take
approximately 20 minutes.
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Blood Sampling: We will obtain about 5 ml of blood (about 1 teaspoon) prior to the first
test session in order to extract DNA and determine specific genotypes. These blood
samples will be obtained from an arm vein.

DNA Sampling: We will extract a sample of your DNA from your blood sample. The
DNA will be stored in our laboratory, but the sample will be coded so that no one except
the investigators can detect which sample is yours. The DNA testing will involve
determining your sequence of DNA for a specific gene that may be related to the
effectiveness of the supplement. The results of this genetic testing will only be available
to the primary investigator and you. These results will not be made public and will be
stored in a locked file cabinet. Your samples and data will be discarded after a five year
period; or earlier if requested by you.

Confidentiality
The results of this research will be presented at conferences and published in exercise
science journals. The results of this project will be coded in such a way that your identity
will not be attached to the final form of this study. The researcher retains the right to use
and publish non-identifiable data. However, you can ask that your data be removed from
the study at any point prior to presentation and publication. While individual responses
are confidential, aggregate data will be presented representing averages or generalizations
about the responses as a whole. All data will be stored in a secure location accessible
only to the researcher. Final aggregate results will be made available to you upon
request.
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Participation & Withdrawal
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without consequences of
any kind. Your right to withdraw includes the right to request that your DNA and blood
samples be discarded at any time.

Questions
If you have questions or concerns during the time of your participation in this study, or
after its completion or you would like to receive a copy of the final aggregate results of
this study, please contact: Christopher J. Womack, Ph.D. at womackcx@jmu.edu or by
phone at 540-568-6515.
Questions about Your Rights as a Research Subject
Dr. David Cockley
Chair, Institutional Review Board
James Madison University
(540) 568-2834
cocklede@jmu.edu

Giving of Consent
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I
certify that I am at least 18 years of age.
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Name of Participant (Printed)

Name of Researcher(s) (Printed)

Name of Participant (Signed)

Name of Researcher(s) (Signed)

Date

Date
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Appendix II
AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
Assess your health status by marking all true statements

History
You have had:
a heart attack
heart surgery
cardiac catheterization
coronary angioplasty (PTCA)
pacemaker/implantable cardiac
defibrillator/rhythm disturbance
heart valve disease
heart failure

If you marked any of these statements
in this section, consult your physician
or other appropriate health care
provider before engaging in exercise.
You may need to use a facility with a
medically qualified staff.

heart transplantation
congenital heart disease

Symptoms
You experience chest discomfort with exertion
You experience unreasonable breathlessness
You experience dizziness, fainting, or blackouts
You take heart medications
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Other Health Issues
You have diabetes
You have asthma or other lung disease
You have burning or cramping sensation in your lower
legs when walking short distances
You have musculoskeletal problems that limit your
physical activity
You have concerns about the safety of exercise
You take prescription medication(s)

Cardiovascular risk factors
You are a man older than 45 years
You are a woman older than 55 years, have had a
hysterectomy, or are postmenopausal
You smoke, or quit smoking within the previous 6 months
Your blood pressure is > 140/90 mmHg
You do not know your blood pressure
You take blood pressure medication
Your blood cholesterol level is > 200 mg/dl
You do not know your cholesterol level

If you marked two or more of the
statements in this section, you
should consult your physician or
other appropriate health care
provider before engaging in
exercise. You might benefit from
using a facility with a
professionally qualified exercise
staff to guide your exercise
program.

You have a close blood relative who had a heart attack or
heart surgery before age 55 (father or brother) or age 65
(mother or sister)
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You are physically inactive (i.e. you get < 30 minutes of
physical activity on at least 3 days of the week)
You have a BMI > 30 kgm2 or waist circumference
> 102 cm (men) or > 88 cm (women)

None of the above

You should be able to exercise safely
without consulting your physician or
other appropriate health care provider
in a self-guided program or almost any
facility that meets your exercise
program needs.
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Appendix III
Subject Prescreening Information
Please Complete the Following:
Gender:

Male

Female (circle one)

Age (yrs):
Height (inches):
Weight (lbs):
Average Exercise Habits over the Past 2 Months:
Avg. # days of exercise per week:
Avg. amount of time per bout of exercise:
Do you have a muscle or joint injury that precludes the completion of the exercise
protocol? Explain.

Do you currently use medications for relief of pain and/or soreness? Explain.

Do you have a blood clotting disorder (haemophilia, thrombocytopenia, etc)?

Do you currently use blood-thinning medications (Coumadin, etc)?

Do you currently use cardiac medications (Digoxin, Digitalis, etc)?
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